RETA Stock News

The stock price of Reata Pharmaceuticals Inc (NASDAQ: RETA) increased by over 14% pre-market. This is why it happened.

PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced tha

The major indices have all jumped as jobless claims fell to a fresh pandemic low. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to give y

Going into today, the Dow Jones continued its sell-off and fell more than 150 points while the S&P 500 lost 0.6% and the Nasdaq dipped more than 1%. Our AI has identified the following stocks ra

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call Transcript

ANNOUNCES FDA ACCEPTED FOR FILING REATA'S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME

PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced tha

PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe

The shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) have received a price target of $155 by Barclays. These are the details.

Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies

PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced t

PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced t

Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome.